Aloja

Aloja

pregabalin

Manufacturer:

Mylan Healthcare

Distributor:

DKSH
Concise Prescribing Info
Contents
Pregabalin
Indications/Uses
Peripheral & central neuropathic pain, generalised anxiety disorder (GAD) in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalisation. Management of fibromyalgia.
Dosage/Direction for Use
Neuropathic pain Initially 150 mg daily as 2 or 3 divided doses, may be increased to 300 mg daily after 3-7 days interval. Max: 600 mg daily after additional 7-day interval. Epilepsy Initially 150 mg daily as 2 or 3 divided doses, may be increased to 300 mg daily after 1 wk. Max: 600 mg daily after an additional wk. GAD Initially 150 mg daily, may be increased to 300 mg daily after 1 wk, then to 450 mg daily following an additional wk. Max: 600 mg daily after an additional wk. Fibromyalgia Initially 75 mg bd, may be increased to 150 mg bd w/in 1 wk or further increase to 225 mg bd. Max: 600 mg daily after an additional wk. CrCl ≥60 mL/min Initially 150 mg daily in 2 or 3 divided doses. Max: 600 mg daily, CrCl ≥30-<60 mL/min Initially 75 mg daily in 2 or 3 divided doses. Max: 300 mg daily, CrCl ≥15-<30 mL/min Initially 25-50 mg daily in 1 or 2 divided doses. Max: 150 mg daily, CrCl <15 mL/min Initially 25 mg daily as single dose. Max: 75 mg daily. Supplementary dose following haemodialysis Initially 25 mg daily as single dose. Max: 100 mg daily.
Administration
May be taken with or without food.
Contraindications
Special Precautions
Discontinue use if hypersensitivity occurs. Increased risk of suicidal thoughts or behavior. Monitor for history of drug abuse & signs of misuse or abuse or dependence eg, development of tolerance, dose escalation, drug-seeking behavior. Dizziness, somnolence, loss of consciousness, confusion & mental impairment; loss of or blurred vision or other changes of visual acuity; reduced lower GIT function; encephalopathy. CV compromised patients; diabetic patients. W/drawal symptoms. Avoid abrupt discontinuation. Concomitant use w/ anti-spasticity agents. May affect ability to drive & use machines. Women of childbearing potential should use effective contraception. Not to be used during pregnancy. Lactation. Childn <12 yr & adolescents 12-17 yr. Elderly >65 yr.
Adverse Reactions
Dizziness, somnolence, headache. Nasopharyngitis; increased appetite; euphoric mood, confusion, irritability, disorientation, insomnia, decreased libido; ataxia, abnormal coordination, tremor, dysarthria, amnesia, memory impairment, disturbance in attention, paraesthesia, hypoaesthesia, sedation, balance disorder, lethargy; blurred vision, diplopia; vertigo; vomiting, nausea, constipation, diarrhoea, flatulence, abdominal distension, dry mouth; muscle cramp, arthralgia, back pain, pain in limb, cervical spasm; erectile dysfunction; peripheral oedema, oedema, abnormal gait, fall, feeling drunk & abnormal, fatigue; increased wt.
Drug Interactions
Potentiated ethanol & lorazepam effects. Resp failure & coma w/ other CNS depressants. Additive impairment of cognitive & gross motor function w/ oxycodone. Reduced lower GIT function w/ opioid analgesics.
MIMS Class
Anticonvulsants / Drugs for Neuropathic Pain
ATC Classification
N03AX16 - pregabalin ; Belongs to the class of other antiepileptics.
Presentation/Packing
Form
Aloja hard cap 150 mg
Packing/Price
3 × 10's
Form
Aloja hard cap 75 mg
Packing/Price
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in